GSK plc at UBS Global Healthcare Conference Transcript
All right. Good morning, everyone. Welcome back to day 2 of the UBS Global Healthcare Conference. My name is Laura Sutcliffe, I am a pharmaceuticals analyst here at UBS. And it's my great pleasure to have with me this morning, Dr. Kimberly Smith, who is the Head of R&D at ViiV Healthcare, which most of you will know is GSK's HIV business, although, of course, it's a JV with Pfizer and Shionogi.
So Kim, welcome. It would be great if you could start just by talking -- just introducing yourself and talking a little bit about kind of where you're leading the HIV business at GSK at the moment, and then we'll get stuck into some more detailed questions.
In the audience, if you have questions, please scan the QR code. You're just a couple of clicks away from appearing on this iPad, and we'll get your questions answered.
Excellent. So as Laura said, I'm head of R&D for ViiV
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |